Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.

@article{Bonifazi2019AcuteGP,
  title={Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.},
  author={Francesca Bonifazi and Carlos Solano and Christine Wolschke and Mariarosaria Sessa and Francesca Patriarca and Francesco Zallio and Arnon Nagler and Carmine Selleri and Antonio Maria Risitano and Giuseppe Messina and Wolfgang Andreas Bethge and Pilar Herrera and Anna Sureda and Angelo Michele Carella and Michele Cimminiello and Stefano Guidi and J{\"u}rgen Finke and Roberto Sorasio and Christelle Ferr{\'a} and Jorge Sierra and Domenico Russo and Edoardo Benedetti and Giuseppe Milone and Fabio M. Benedetti and Marion Heinzelmann and Domenico Pastore and Manuel Jurado and Elisabetta Terruzzi and Franco Narni and Andreas V{\"o}lp and Francis Ayuketang Ayuk and Tapani Ruutu and Nicolaus Kr{\"o}ger},
  journal={The Lancet. Haematology},
  year={2019},
  volume={6 2},
  pages={
          e89-e99
        }
}

Figures from this paper

Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors

TLDR
It is confirmed that PTCy+T/MMF treatment effectively prevented acute and chronic GVHD and limited NRM to unprecedented low rates without loss of disease control efficacy in an expanded patient cohort.

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

TLDR
Overall, these recommendations can be used for a proper and safe application of polyclonal ATG/ATLG to prevent GvHD after allogeneic HSCT to prevent graft-versus-host disease.

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation

TLDR
The choice of ATLG dose has significant impact on IR but not on GVHD after MUD-allo-SCT, and higher doses are associated with delayed engraftment and increased infections.

Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies

TLDR
Rabbit antithymocyte globulin in the current protocol for GVHD prophylaxis was well tolerable and efficacious and led to a significant reduction in the incidence of cGVHD without increased relapse risk and nonrelapse mortality.

Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study

TLDR
PT-Cy and ATLG was overall safe and translated into a low rate of chronic GvHD incidence, and long-term immune reconstitution on the CD4+ subsets did not translate into higher rate of relapse or viral infection.

Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors

TLDR
It is shown that low-dose ATG effectively suppresses chronic GVHD in unrelated PBSCT, and ALC before ATG may be a potential predictor for GV HD and relapse.

Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center.

  • A. SalhotraS. Hui A. Stein
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2019

Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT

TLDR
Long-term outcome for AML patients in CR two years after transplantation is not impacted by donor type, and no impact of donor type was observed on relapse incidence or non-relapse mortality.

Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis

TLDR
Although ATG had no significant effect on relapse, RFS, and NRM, it significantly reduced the occurrence and severity of GVHD, improved the GRFS,and reduced the number and dose of immunosuppressants in patients undergoing allo-HSCT.

References

SHOWING 1-10 OF 35 REFERENCES

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

TLDR
The results suggest that the use of ATG with fludarabine and 4 days intravenous busulfan followed by HLA-identical sibling donor allogeneic stem cell transplantation for acute myeloid leukemia improves overall transplant outcomes due to reduced incidence of chronic GVHD without increased relapse risk.

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

TLDR
Overall, these recommendations can be used for a proper and safe application of polyclonal ATG/ATLG to prevent GvHD after allogeneic HSCT to prevent graft-versus-host disease.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

TLDR
The inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia resulted in a significant reduction in chronic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical sibling.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

TLDR
Data suggest that posttransplantation cyclophosphamide (PTCy) minimizes the global immunosuppressive burden experienced by patients undergoing HLA-matched alloBMT.

Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties

TLDR
This large EBMT survey suggests the potential of allogeneic HSCT to induce long-term disease control in a large proportion of refractory ADs, with acceptable toxicities and NRM, especially in younger patients.